VivoSeq
Other

Breakthrough Pain

0

Pipeline Programs↗

1

Active Trials↗

4

Companies Involved↗

Breakthrough Pain is an early-stage landscape with 0 programs across 4 companies. The most active players are Takeda, Kyowa Kirin Co., Ltd., Johnson & Johnson Taiwan Ltd.

Intelligence

Pipeline Metrics

Competitive Density

6/100

Pipeline Velocity

0/100

Mech. Concentration

N/A

Completion Rate

76/100

Attrition Rate

23/100

Competition

Competitive Landscape

Bubble size = clinical trials

Approved
Phase 3
Phase 2
Phase 1
Preclinical

Key Players

Top Companies Companies ranked by the number of pipeline programs they run for this disease.

Takeda logo

Takeda

0 programs

PreclinicalKyowa Kirin Co., Ltd. logo

Kyowa Kirin Co., Ltd.

0 programs

PreclinicalJ

Johnson & Johnson Taiwan Ltd

0 programs

PreclinicalZ

ZARS Pharma Inc.

0 programs

Preclinical

Pipeline

Programs by Phase

No pipeline programs currently tracked for this disease.

Analysis

Trial Status

26

clinical trials

Completed19 · 73%
Terminated4 · 15%
Withdrawn2 · 8%
Recruiting1 · 4%

Clinical Trials

Trial Activity

26 trials

PIEB Compared With CEI on Breakthrough Pain in Nulliparous Women
Recruiting·HHoly Family Hospital, Nazareth, Israel·N/A·NCT06494280·240 enrolled
Evaluating the Safety and Tolerability of OraVescent Fentanyl for Opioid Tolerant Patients With Noncancer Related Breakthrough Pain
Completed·CCephalon·Phase 3·NCT00228605·500 enrolled
Comparison of Nasal Fentanyl and Oral Transmucosal Fentanyl (Actiq) in Cancer Breakthrough Pain (FT-019-IM)
Completed·NNycomed·Phase 3·NCT00496392·115 enrolled
Efficacy/Safety Study of ACTIQ® for Opioid-Tolerant Children and Adolescents With Breakthrough Pain (BTP)
Completed·CCephalon·Phase 2·NCT00236041·38 enrolled
A Phase III Clinical Study of KW-2246 for Breakthrough Pain in Cancer Patients
Completed·Kyowa Kirin Co., Ltd. logoKyowa Kirin Co., Ltd.·Phase 3·NCT00684632·51 enrolled
Oral Piroxicam Versus Buccal Fentanyl in Breakthrough Pain
Completed·TTanta University·N/A·NCT02382653·100 enrolled
Sublingual Methadone for the Management of Cancer Breakthrough Pain
Completed·AAHS Cancer Control Alberta·Phase 1·NCT00125294·10 enrolled
Extension Study of ACTIQ Treatment for Children and Adolescents With Breakthrough Pain
Completed·CCephalon·Phase 2·NCT00236093
Comparison of Epidural Fentanyl and Clonidine for Breakthrough Pain
Completed·—·Phase 4·NCT01846221·101 enrolled
Intranasal Fentanyl for the Treatment of Breakthrough Pain in Cancer Patients (FT-017-IM)
Completed·NNycomed·Phase 2·NCT00345735·150 enrolled
A Study for the Evaluation of the Safety, Tolerability, and Efficacy of ARX-F02 (Sufentanil NanoTab) Compared to Placebo in the Treatment of Cancer Breakthrough Pain
Completed·TTalphera, Inc·Phase 2·NCT00833040·34 enrolled
An Open Label Study to Evaluate Safety, Tolerability and Clinical Utility of ULTRACET® (37.5mg Tramadol Hydrochloride/325mg Acetaminophen) for the Treatment of Breakthrough Pain in Cancer Patients
Completed·JJohnson & Johnson Taiwan Ltd·Phase 4·NCT00576173·60 enrolled
Treatment of Breakthrough Pain in Opioid Tolerant Cancer Patients
Completed·CCephalon·Phase 3·NCT00105287·100 enrolled
OraVescent Fentanyl (OVF) for the Treatment of Breakthrough Pain in Opioid Tolerant Cancer Patients
Completed·CCephalon·Phase 3·NCT00105937·300 enrolled
Efficacy and Tolerability of Intranasal Fentanyl Spray for the Treatment of Breakthrough Pain in Cancer Patients Older Than 18 Years
Completed·Takeda logoTakeda·N/A·NCT00994760·131 enrolled
Page 1 of 2

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)